Tiziana Life Sciences Ltd

Stock Chart, Company Information, and Scan Results

$1.68(as of Jan 16, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tiziana Life Sciences Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$1.68
Ticker SymbolTLSA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees9
CountyUSA
Market Cap$201.9M

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd In Our Stock Scanner

As of Jan 20, 2026
As of ---
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.